N-Lorem accepted Ireland as a patient in 2021. They have made incredible progress on the research and development of a personalized medicine for her. Ireland's program is estimated to cost $1.2 million. N-Lorem is a nonprofit and generously provides their medicines for free, for the life of the patient.
Antisense Oligonucleotides (ASOs) are designed to bind precisely with RNA, modifying the process of creating a disease-causing protein. ASOs are short strands of modified DNA that can specifically target the transcripts of a defective gene to modify the product of that gene.
An ASO is a genetic based treatment that we hope will improve several of her symptoms and has the possibility to slow the progression of her neurodegenerative disease. 7/7 N-Lorem patients show evidence of clinically important benefit with no adverse reactions.